The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
Subscribe To Our Newsletter & Stay Updated
